Cologne, Germany / Basel, Switzerland, 16 March 2017 – Lonza now offers a comprehensive portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing, further strengthening its position as a leader in cell discovery. This expansion of Lonza’s primary cells range is the result of last year’s acquisition of renowned hepatocyte provider, Triangle Research Laboratories (TRL). By combining TRL’s expertise with Lonza’s quality control, large production capacity and scientific support, Lonza can now provide a source of high-quality hepatocytes for in-vitro drug metabolism and pharmacokinetic studies or for vital research into diseases such as Malaria and Hepatitis B.
Lonza’s new range of ADME-Tox products includes both fresh and cryopreserved human and animal hepatocytes, supporting researchers with a variety of in-vitro applications, including studies into drug metabolism and toxicity, drug-transporter activity and drug-drug interactions. The new hepatocyte portfolio also features hepatic non-parenchymal cells, such as stellate and Kupffer cells, which can improve the translatability of in-vitro toxicity testing and pharmacokinetics research to clinical trials.
Lonza’s hepatocytes are pre-qualified for a variety of different applications, which helps to reduce time and money spent evaluating cells for specific experiments within the laboratory. The new range also includes supporting ADME-Tox products such as specialized hepatocyte media and cell culture systems, helping to optimize hepatocyte culture performance for in-vitro drug screening or for research into drug-induced liver injury and other important liver diseases.
“With many conclusions regarding the pharmacokinetics and safety of a drug candidate being drawn from the results of in-vitro studies on human hepatocytes, researchers need a source of hepatocytes they can rely on,” said Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. “By blending the extensive expertise of Lonza and TRL, our new hepatocyte portfolio will address the needs of the scientific community, offering hepatocytes that produce consistent and reliable results for ADME-Tox testing and for research into liver-associated diseases.”
For more information about Lonza’s hepatocyte portfolio, please visit: http://www.lonza.com/products-services/bio-research/adme-tox.aspx
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Lonza Contact Information
Lonza Cologne GmbH, Manager Marketing Communications, Petra Haberkamm Tel +49 221 991990 Fax +49 221 99199498 [email protected]
Lonza Group Ltd, Head Corporate Communications, Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9540 [email protected]
Lonza Group Ltd, Head External Communications, Constance Ward Tel +41 61 316 8840 Fax +41 61 316 9840 [email protected]
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.